As researchers continue to study the impacts of biofilms on wounds, individuals living with chronic wounds often experience a negative impact on their overall physical and mental health, especially for those whose wounds continue for months or even years. Chronic wound patients commonly report concerns with pain, malodour, wound appearance, and discomfort with dressings that negatively impact their daily lives.
The T.I.M.E. (tissue management, infection/inflammation, moisture, edge of wound) framework is often used to assess a wound and determine the treatment protocol. To suppress biofilm activity in a wound typically requires multiple approaches to treatment, focused on the biofilm but not impacting the innate healing mechanisms within the body.
The T.I.M.E. framework has been developed to help healthcare practitioners to better assess and handle patients who are impacted by wounds and provide consistent documentation for improved outcomes. It helps to identify a baseline for wound care that can be measured during and following treatment, such as the addition of a wound gel to a patient’s treatment plan. It can help to determine whether a wound is acute or chronic, as a chronic wound typically gets “stuck” in the inflammatory stage of the T.I.M.E. framework and does not appear to be significantly healing after 30 days.
Example of approach to treating chronic wounds
Treatment approaches for eradicating biofilms from wounds include debridement of the wound to promote faster healing and reduce the biofilm burden. New technology to address biofilms in wounds are emerging onto the market. Topical antimicrobial treatments such as Kane Biotech’s coactiv+ Antimicrobial Hydrogel, which has recently been a 510(k) pre-market submission to the F.D.A., use Kane’s patented coactiv+ technology in a thermo-reversible gelling system, provides ease of use and is optimized for sensitive wounds. Kane aims to make the wound gel accessible to patients, taking into consideration current reimbursement levels under the surgical dressing policy in the U.S. Additionally, Kane’s DispersinB® Hydrogel, which received additional funding from the U.S. Army, is a new innovative technology formulated to treat biofilm-mediated antimicrobial resistance in non-healing chronic wounds. It is expected to begin clinical trials in 2023.
The outcome of chronic wounds is impaired healing, as the wound typically remains in the inflammatory phase, elevating protease activity, and creating a hostile environment for healing. This environment must change for the chronic wound to improve.
With 80 patents and patents pending, Kane Biotech is a leader in biofilm research. Kane has laboratory and clinical evidence that these technologies have the potential to significantly improve the ability to prevent and destroy biofilms. This is why Kane is considered THE Biofilm Company, as it is leading the advancement of technologies and products that break up biofilms and destroy bacteria.
Kane Biotech dispose d'un portefeuille croissant de technologies basées sur ses recherches en cours sur la formation des biofilms et sur la manière dont ce processus peut être perturbé. Kane s'engage à développer des produits pour répondre à la demande de composés anti-biofilm sûrs et efficaces pour une variété d'industries et d'applications.